Mc Callion Orla

Consejero General en ULTIMOVACS ASA .

Fortuna: - $ al 31/05/2024

Health Technology

Consumer Services

Cargos activos de Mc Callion Orla

Empresas	Cargo	Inicio	Fin
ULTIMOVACS ASA	Consejero General	01/10/2021	-

Empresas	Cargo	Inicio	Fin
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Consejero General	01/10/2012	01/10/2021

Queen's University

Doctorate Degree

Internacional

Operativa

General Counsel	2
Doctorate Degree	1

Sectorial

Health Technology	3
Consumer Services	2

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas cotizadas	1
ULTIMOVACS ASA	Health Technology

Empresas privadas	1
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology

Empresas privadas

Health Technology